Hepatitis Monthly

Published by: Kowsar

Predictors of Pegylated Interferon Alpha and Ribavirin Efficacy and Long-Term Assessment of Relapse in Patients With Chronic Hepatitis C: A One-Center Experience From China

Qin Wu 1 , Feng Yu Zhan 2 , En Qiang Chen 1 , Cong Wang 2 , Zhen Zhen Li 2 and Xue Zhong Lei 1 , *
Authors Information
1 Infectious Diseases Center, West China Hospital, Sichuan University, Chengdu, China
2 West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China
Article information
  • Hepatitis Monthly: June 01, 2015, 15 (6); e28836
  • Published Online: June 23, 2015
  • Article Type: Research Article
  • Received: March 23, 2015
  • Revised: April 18, 2015
  • Accepted: May 10, 2015
  • DOI: 10.5812/hepatmon.15(6)2015.28836

To Cite: Wu Q, Zhan F Y, Chen E Q, Wang C, Li Z Z, et al. Predictors of Pegylated Interferon Alpha and Ribavirin Efficacy and Long-Term Assessment of Relapse in Patients With Chronic Hepatitis C: A One-Center Experience From China, Hepat Mon. 2015 ;15(6):e28836. doi: 10.5812/hepatmon.15(6)2015.28836.

Abstract
Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4): 1335-74[DOI][PubMed]
  • 2. Sarrazin C, Berg T, Ross RS, Schirmacher P, Wedemeyer H, Neumann U, et al. [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol. 2010; 48(2): 289-351[DOI][PubMed]
  • 3. Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res. 2014; 107: 23-30[DOI][PubMed]
  • 4. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014; 370(3): 211-21[DOI][PubMed]
  • 5. Gordon SC, Reddy KR, Jacobson IM, Poordad F, Bronowicki JP, Bacon B, et al. Boceprevir plus peginterferon alpha-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response. J Clin Gastroenterol. 2014; 48(5): 435-43[PubMed]
  • 6. Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW. The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus. Clin Infect Dis. 2015; [DOI][PubMed]
  • 7. Koh C, Heller T, Haynes-Williams V, Hara K, Zhao X, Feld JJ, et al. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Ther. 2013; 37(9): 887-94[DOI][PubMed]
  • 8. Watanabe S, Kobayashi Y, Kawata K, Noritake H, Chida T, Nagasawa M, et al. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders. Intern Med. 2015; 54(3): 273-9[DOI][PubMed]
  • 9. Sandoughdaran S, Alavian SM, Sharafi H, Behnava B, Salimi S, Mehrnoush L, et al. Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy. Hepat Mon. 2015; 15(1)[DOI][PubMed]
  • 10. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011; 55(2): 245-64[DOI][PubMed]
  • 11. Dong ZX, Zhou HJ, Xiang XG, Guo SM, Zhuang Y, Zhao GD, et al. IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population. J Dig Dis. 2015; 16(2): 90-7[DOI][PubMed]
  • 12. Khubaib B, Idrees M, Afzal S, Wasim M. The genotype CC of IL28B SNP rs12979860 is significantly associated with sustained virological response in chronic HCV Pakistani patients. J Dig Dis. 2015; [DOI][PubMed]
  • 13. Gill U, Aziz H, Gill ML. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan. Int J Infect Dis. 2013; 17(11)-21[DOI][PubMed]
  • 14. Wisniewska-Ligier M, Pawlowska M, Pilarczyk M, Halota W, Wozniakowska-Gesicka T. Efficacy of pegylated interferon alpha-2b and ribavirin in chronic hepatitis C virus (genotypes 1 and 4) infection. J Pediatr Gastroenterol Nutr. 2013; 57(6): 694-9[DOI][PubMed]
  • 15. Toyoda H, Kumada T, Shimada N, Takaguchi K, Ide T, Sata M, et al. Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin. BMC Infect Dis. 2012; 12: 324[DOI][PubMed]
  • 16. Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, Akuta N, et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci. 2009; 54(6): 1317-24[DOI][PubMed]
  • 17. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54(4): 1433-44[DOI][PubMed]
  • 18. Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther. 2013; 37(10): 921-36[DOI][PubMed]
  • 19. De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, Soffredini R, et al. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology. 2012; 55(2): 336-42[DOI][PubMed]
  • 20. Sarwar S, Ryan EJ, Iqbal M, McCormick PA, O'Farrelly C, Hegarty J. Rapid, early and sustained virological responses in a cohort of Irish patients treated with pegylated interferon and ribavirin for chronic hepatitis C virus infection. Ir J Med Sci. 2012; 181(1): 53-8[DOI][PubMed]
  • 21. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol. 2011; 55(1): 69-75[DOI][PubMed]
  • 22. Milan M, Boninsegna S, Scribano L, Lobello S, Fagiuoli S, Fabris P, et al. Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients? Infection. 2012; 40(2): 173-9[DOI][PubMed]
  • 23. Kurosaki M, Hiramatsu N, Sakamoto M, Suzuki Y, Iwasaki M, Tamori A, et al. Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis. Antivir Ther. 2012; 17(1): 35-43[DOI][PubMed]
  • 24. Tsui JI, Currie S, Shen H, Bini EJ, Brau N, Wright TL, et al. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study. Dig Dis Sci. 2008; 53(3): 809-14[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments